Latest Innovation News

Whitebark Energy has appointed Nik Sykiotis as CEO, positioning the company to advance its strategic focus on natural hydrogen, helium, and hydrocarbons. Sykiotis’s operational expertise is expected to steer Whitebark through its next growth phase.

State Gas Limited has raised $3.2 million through convertible notes issued at a 33% premium, alongside a $0.5 million director debt conversion, to accelerate pre-development of its Rolleston West coal seam gas project following a maiden 2P reserve certification.

Anax Metals has completed a $2.4 million strategic placement with mining group Gold Valley at a 37.5% premium, while securing a $3.5 million loan to repay convertible notes, positioning the Whim Creek copper project for near-term development.

Locksley Resources has raised A$17 million in an oversubscribed placement led by U.S. institutional investors, accelerating its strategy to develop a domestic supply chain for antimony and rare earths in California.

Eden Innovations has landed its largest order yet from Holcim Ecuador, signalling accelerating demand for its EdenCrete®Pz7 concrete additive and reinforcing its growth trajectory.

Cobalt Blue Holdings has raised $5.3 million through a discounted placement to advance its Kwinana Cobalt Refinery and Broken Hill projects, reinforcing its position in the critical minerals sector.

Imugene Limited has received positive feedback from the FDA, aligning key requirements to progress its azer-cel therapy into a pivotal clinical trial, underscoring its growing promise in blood cancer treatment.

Ovanti Limited’s US subsidiary has secured a key partnership with Mastercard’s Finicity to enhance its upcoming Flote BNPL platform, aiming to revolutionize consumer finance with real-time data insights.

Sparc Hydrogen has appointed Alana Barlow as its inaugural CEO, marking a strategic move to accelerate commercialisation of its innovative photocatalytic water splitting technology for green hydrogen.

Talius Group appoints seasoned executive Pat Howard as CEO, with founder Graham Russell shifting to a strategic growth role, signalling a new phase of expansion and innovation.

Chimeric Therapeutics has won FDA Orphan Drug Designation for its CHM CDH17 CAR-T therapy targeting gastric cancer, advancing its clinical development with regulatory incentives and potential market exclusivity.

CLINUVEL Pharmaceuticals is significantly expanding its VALLAURIX RD&I Centre in Singapore with a five-year strategic investment, aiming to become a global leader in advanced peptide drug delivery.